Biotest AG (Biotest AG) Change In Receivables : $0.0 Mil (TTM As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Biotest AG Change In Receivables?

Biotest AG's change in receivables for the quarter that ended in Mar. 2024 was $0.0 Mil. It means Biotest AG's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .

Biotest AG's change in receivables for the fiscal year that ended in Dec. 2023 was $0.0 Mil. It means Biotest AG's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .

Biotest AG's Accounts Receivable for the quarter that ended in Mar. 2024 was $218.5 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Biotest AG's Days Sales Outstanding for the three months ended in Mar. 2024 was 85.23.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Biotest AG's liquidation value for the three months ended in Mar. 2024 was $-489.1 Mil.

Biotest AG Change In Receivables Historical Data

The historical data trend for Biotest AG's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotest AG Change In Receivables Chart

Biotest AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

Biotest AG Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Biotest AG Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

Biotest AG (OTCPK:BIESF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Biotest AG's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	218.478	/	233.913	*	91
=	85.23

2. In Ben Graham's calculation of liquidation value, Biotest AG's accounts receivable are only considered to be worth 75% of book value:

Biotest AG's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	107.391	-	998.804	+	0.75 * 218.478	+	0.5 * 476.848
=	-489.1

Biotest AG Change In Receivables Related Terms

Thank you for viewing the detailed overview of Biotest AG's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Biotest AG (Biotest AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biotest AG (OTCPK:BIESF) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

BIO3:Germany BIO3:Austria

Address

Landsteinerstrasse 5, Dreieich, DEU, 63303

Website

https://www.biotest.com

Biotest AG is a supplier of biological medicines. The company produces its products from human blood plasma or manufactured by using biotechnology methods. It is engaged in the area of hematology, clinical immunology, and intensive care medicine. The operating business segments are Therapy, Plasma and Services, and Other segments. It generates maximum revenue from the Therapy segment. Geographically, it derives a majority of revenue from Central Europe and also has a presence in other countries.